[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schenkel et al., 2011 - Google Patents

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors

Schenkel et al., 2011

Document ID
3014090011181067304
Author
Schenkel L
Huang X
Cheng A
Deak H
Doherty E
Emkey R
Gu Y
Gunaydin H
Kim J
Lee J
Loberg R
Olivieri P
Pistillo J
Tang J
Wan Q
Wang H
Wang S
Wells M
Wu B
Yu V
Liu L
Geuns-Meyer S
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of- function mutation in the majority of patients with myeloproliferative disorders (MPD). Here …
Continue reading at pubs.acs.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Similar Documents

Publication Publication Date Title
Schenkel et al. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors
Brown et al. Where do recent small molecule clinical development candidates come from?
Davis et al. Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof
Thorarensen et al. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2 S, 5 R)-5-((7 H-Pyrrolo [2, 3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl) prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Hanan et al. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors
Tovell et al. Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader
Ren et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region–abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib
Zhao et al. Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes
Li et al. Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3
Howard et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity
Lawrence et al. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors
Kulagowski et al. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors
Henderson et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7 H-pyrrolo [2, 3-d] pyrimidin-5-yl] benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor
Chen et al. Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling
Ward et al. Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2
Marineau et al. Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7
Goldstein et al. Discovery of 6-(2, 4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl) propylamino]-8-methyl-8 H-pyrido [2, 3-d] pyrimidin-7-one (Pamapimod) and 6-(2, 4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2 H-pyran-4-ylamino) pyrido [2, 3-d] pyrimidin-7 (8 H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase
Li et al. Discovery of a series of 2, 5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity
Lou et al. Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies
Goodfellow et al. Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3
Caldwell et al. Identification of 4-(4-aminopiperidin-1-yl)-7 H-pyrrolo [2, 3-d] pyrimidines as selective inhibitors of protein kinase B through fragment elaboration
Soth et al. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models
Safina et al. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition
McHardy et al. Discovery of 4-amino-1-(7 H-pyrrolo [2, 3-d] pyrimidin-4-yl) piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)
Boga et al. MK-8353: discovery of an orally bioavailable dual mechanism ERK inhibitor for oncology